PsiThera Unveiled with Newly Appointed CEO and $47.5 Million Series A to Advance Oral Medicines for Validated I&I Targets
Watertown, MA, December 10, 2025 — PsiThera, a biotech company harnessing biologically relevant protein states and computational intelligence to create oral drugs for diseases long-constrained by injectable-only approaches, announced today that it has closed a $47.5 million Series A financing and appointed Eric Shaff as Chief Executive Officer. The equity round was led by Samsara Biocapital…